Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of mRNA-1647 CMV vaccine in healthy participants 16–40 years
2020-006051-17Phase 3Active
- Sponsor
- Moderna Inc
- Start
- Oct 2021
- Modality
- Vaccines & Immunotherapeutics, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 3, randomised, single-blind trial in cytomegalovirus disease (CMV) comparing mRNA-1647 with Placebo (2 arms). Primary endpoint: Primary CMV infection. Started Oct 2021; status: active.
02
Drugs
mRNA-1647
03
Conditions
cytomegalovirus disease (CMV)
Beyond the preview
Go deeper on 2020-006051-17.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-006051-17.